Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xanamem dose-ranging study in healthy elderly volunteers
NCT04983368Phase 2Completed
- Sponsor
- Actinogen Medical Limited
- Start
- Jun 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of emestedastat in Alzheimer's disease (AD), Mild Cognitive Impairment (MCI), sponsored by Actinogen Medical Limited. Started Jun 2021; status: completed.
02
Drugs
emestedastat
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT04983368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04983368.